Trial · NCT01739790

N-Acetylcysteine for Patients With COPD and Chronic Bronchitis

NCT01739790, Not applicable, Terminated, University of Minnesota; results first posted 2017-09-13

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. N-Acetylcysteine for Patients With COPD and Chronic Bronchitis. Trials, record NCT01739790. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01739790

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: N-Acetylcysteine for Patients With COPD and Chronic Bronchitis
NCT number: NCT01739790
Status: Terminated
Phases: Not applicable
Enrollment: 51 participants, actual
Lead sponsor: University of Minnesota
Conditions: COPD, Chronic Bronchitis
Interventions: N-Acetylcysteine, Placebo
First posted: 2012-12-03
Last updated: 2017-09-13
Results first posted: 2017-09-13

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Changes in the Saint George's Respiratory Questionnaire	Baseline to 8 weeks	The St. George's Respiratory Questionnaire (SGRQ) is scored on a scale of 1 to 100 with 100 representing the worst respiratory health status. The instrument is self-administered at baseline and again after 8-weeks of treatment.

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Changes in the Saint George's Respiratory Questionnaire	Baseline to 8 weeks		units on a scale	MEAN

Source ClinicalTrials.gov

Results by group8

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Changes in the Saint George's Respiratory Questionnaire	Placebo	Change in SGRQ Symptoms	-9.8	Standard Deviation 17.8	units on a scale
Changes in the Saint George's Respiratory Questionnaire	N-Acetylcysteine	Change in SGRQ Symptoms	-3.5	Standard Deviation 18.6	units on a scale
Changes in the Saint George's Respiratory Questionnaire	Placebo	Change in SGRQ Activity	-3.7	Standard Deviation 14.5	units on a scale
Changes in the Saint George's Respiratory Questionnaire	N-Acetylcysteine	Change in SGRQ Activity	-4.0	Standard Deviation 13.6	units on a scale
Changes in the Saint George's Respiratory Questionnaire	Placebo	Change in SGRQ Impact	-7.5	Standard Deviation 20.1	units on a scale
Changes in the Saint George's Respiratory Questionnaire	N-Acetylcysteine	Change in SGRQ Impact	-4.5	Standard Deviation 19.9	units on a scale
Changes in the Saint George's Respiratory Questionnaire	Placebo	Change in SGRQ Total	-7.1	Standard Deviation 16.1	units on a scale
Changes in the Saint George's Respiratory Questionnaire	N-Acetylcysteine	Change in SGRQ Total	-3.9	Standard Deviation 12.1	units on a scale

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo	24
Overall Study	STARTED	N-Acetylcysteine	27
Overall Study	COMPLETED	Placebo	22
Overall Study	COMPLETED	N-Acetylcysteine	23
Overall Study	NOT COMPLETED	Placebo	2
Overall Study	NOT COMPLETED	N-Acetylcysteine	4

Source ClinicalTrials.gov

Adverse events44

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Rotator cuff repair	Musculoskeletal and connective tissue disorders	Placebo	1	22	1
other	Rotator cuff repair	Musculoskeletal and connective tissue disorders	N-Acetylcysteine	0	23	0
other	Alcohol abuse	Social circumstances	Placebo	1	22	1
other	Alcohol abuse	Social circumstances	N-Acetylcysteine	0	23	0
other	Ruptured Baker's cyst	Musculoskeletal and connective tissue disorders	Placebo	1	22	1
other	Ruptured Baker's cyst	Musculoskeletal and connective tissue disorders	N-Acetylcysteine	0	23	0
other	COPD exacerbation	Respiratory, thoracic and mediastinal disorders	Placebo	3	22	3
other	COPD exacerbation	Respiratory, thoracic and mediastinal disorders	N-Acetylcysteine	5	23	5
other	Nausea	Gastrointestinal disorders	Placebo	1	22	1
other	Nausea	Gastrointestinal disorders	N-Acetylcysteine	2	23	2

1 to 10 of 44Source ClinicalTrials.gov

See all 44 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Placebo	0	22
Total, all-cause mortality	N-Acetylcysteine	0	23
Total, other adverse events	Placebo	9	22
Total, other adverse events	N-Acetylcysteine	13	23
Total, serious adverse events	Placebo	2	22
Total, serious adverse events	N-Acetylcysteine	3	23

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
27143871	RESULT

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
N-Acetylcysteine vs Placebo: deaths from any cause	Trial comparisons
N-Acetylcysteine vs Placebo: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01739790

GET https://conductscience.org/api/trials/v1/NCT01739790/events?page=2

API reference For AI assistants